Efficacy of rituximab in refractory polymyositis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15996082.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We describe the effectiveness of rituximab, an anti-B lymphocyte monoclonal antibody, in a case of refractory polymyositis with interstitial pulmonary disease and anti-Jo-1 autoantibody (antisynthetase syndrome). Rituximab was well tolerated, and its efficacy in inflammatory myositis should be evaluated.
Medical subject headings
- Antibodies, Monoclonal
- Immunologic Factors
- Polymyositis